Aytu Biopharma Inc (AYTU)

$2.56 -0.07 (-2.66%)
Market Cap 27.37M
Revenue (ttm) 66.38M
Net Income (ttm) -13.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -20.43%
Debt to Equity Ratio 1.47
Volume 44,797
Avg Vol 52,100
Day's Range N/A - N/A
Shares Out 10.73M
Stochastic %K 37%
Beta 0.27
Analysts Sell
Price Target $9.67

Company Profile

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 720 437 6580
Website: aytubio.com
Address:
Denver Corporate Center III, Suite 920 7900 East Union Avenue, Denver, United States
Fibonacci5
Fibonacci5 Apr. 10 at 11:37 AM
$AYTU this is getting bot out.
0 · Reply
pamplon
pamplon Apr. 2 at 10:45 PM
$AYTU This is really good news https://app.quotemedia.com/data/downloadFiling?webmasterId=102691&ref=319930169&type=PDF&symbol=AYTU&cdn=f2c683ce4fe38b388f07f88e95c50879&companyName=Aytu+BioPharma%2C+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2026-04-02
3 · Reply
inv1ncible
inv1ncible Mar. 23 at 7:08 PM
$AYTU trash ceo and stock
0 · Reply
inv1ncible
inv1ncible Mar. 20 at 4:48 AM
$AYTU
0 · Reply
Lucas76
Lucas76 Mar. 19 at 9:34 PM
$AYTU Now that's impressive:
0 · Reply
termoil
termoil Mar. 18 at 3:58 PM
$AYTU If the board decides to sell then what would be a fair price per share?
1 · Reply
YourObscureCEOforLife
YourObscureCEOforLife Mar. 17 at 8:51 PM
$AYTU
0 · Reply
Alain_Simard
Alain_Simard Mar. 13 at 1:56 PM
$AYTU the only thing that $AYTU has going for it is that it doesn’t have any Iran exposure
0 · Reply
Love_To_Learn
Love_To_Learn Mar. 11 at 8:47 PM
$CDXS 1.8 key now old beloved sending code now also main 1.8 key creator $AYTU executing !
1 · Reply
mfoxx
mfoxx Mar. 11 at 5:29 PM
$AYTU when delist?
0 · Reply
Latest News on AYTU
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results

Feb 3, 2026, 4:05 PM EST - 2 months ago

Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results

Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

Jan 27, 2026, 4:05 PM EST - 2 months ago

Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

Aytu BioPharma Recaps Investor Day Held on January 20, 2026

Jan 20, 2026, 4:05 PM EST - 2 months ago

Aytu BioPharma Recaps Investor Day Held on January 20, 2026

Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026

Jan 13, 2026, 4:15 PM EST - 3 months ago

Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026

Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City

Jan 12, 2026, 8:00 AM EST - 3 months ago

Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City

Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City

Dec 18, 2025, 9:00 AM EST - 4 months ago

Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City

Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults

Dec 15, 2025, 9:00 AM EST - 4 months ago

Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults

Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Nov 24, 2025, 4:05 PM EST - 5 months ago

Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results

Nov 13, 2025, 4:05 PM EST - 5 months ago

Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results

Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025

Nov 5, 2025, 4:05 PM EST - 5 months ago

Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025

Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)

Oct 28, 2025, 9:00 AM EDT - 6 months ago

Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)

Aytu BioPharma to Present at Upcoming October 2025 Conferences

Oct 10, 2025, 9:00 AM EDT - 6 months ago

Aytu BioPharma to Present at Upcoming October 2025 Conferences

Aytu BioPharma to Present at Upcoming September 2025 Conferences

Sep 24, 2025, 4:15 PM EDT - 7 months ago

Aytu BioPharma to Present at Upcoming September 2025 Conferences

Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)

Sep 23, 2025, 4:05 PM EDT - 7 months ago

Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)

Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025

Sep 16, 2025, 4:05 PM EDT - 7 months ago

Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025

Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)

Jun 25, 2025, 8:00 AM EDT - 10 months ago

Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)

Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)

Jun 23, 2025, 8:00 AM EDT - 10 months ago

Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)

Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan

Jun 9, 2025, 4:30 PM EDT - 11 months ago

Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan

Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock

Jun 6, 2025, 8:01 AM EDT - 11 months ago

Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock

Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States

Jun 6, 2025, 8:00 AM EDT - 11 months ago

Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results

May 14, 2025, 4:05 PM EDT - 11 months ago

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025

May 7, 2025, 4:15 PM EDT - 1 year ago

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025

Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Apr 21, 2025, 4:05 PM EDT - 1 year ago

Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results

Feb 12, 2025, 4:03 PM EST - 1 year ago

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results

Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025

Feb 5, 2025, 5:50 PM EST - 1 year ago

Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025

Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 6, 2025, 9:00 AM EST - 1 year ago

Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Aytu BioPharma Disclosure Notification

Dec 3, 2024, 11:45 PM EST - 1 year ago

Aytu BioPharma Disclosure Notification

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

Nov 22, 2024, 9:00 AM EST - 1 year ago

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

Nov 13, 2024, 4:05 PM EST - 1 year ago

Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024

Nov 6, 2024, 5:20 PM EST - 1 year ago

Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024

Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 14, 2024, 4:15 PM EDT - 1 year ago

Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit

Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada

Oct 1, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada

Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results

Sep 26, 2024, 4:15 PM EDT - 1 year ago

Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results

Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024

Sep 19, 2024, 5:30 PM EDT - 1 year ago

Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024

Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024

Aug 8, 2024, 5:20 PM EDT - 1 year ago

Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024

Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations

Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms

Jun 18, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms

Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results

May 15, 2024, 4:05 PM EDT - 2 years ago

Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results

Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024

May 8, 2024, 4:15 PM EDT - 2 years ago

Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024

Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024

Apr 3, 2024, 9:00 AM EDT - 2 years ago

Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024

Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter

Feb 14, 2024, 4:05 PM EST - 2 years ago

Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter

Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024

Feb 7, 2024, 4:15 PM EST - 2 years ago

Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024

Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Jan 23, 2024, 9:00 AM EST - 2 years ago

Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

Nov 30, 2023, 8:00 AM EST - 2 years ago

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results

Nov 14, 2023, 4:05 PM EST - 2 years ago

Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year

Nov 8, 2023, 8:30 AM EST - 2 years ago

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year

Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023

Nov 7, 2023, 4:15 PM EST - 2 years ago

Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023

Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

Oct 26, 2023, 8:00 AM EDT - 2 years ago

Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023

Oct 9, 2023, 4:15 PM EDT - 2 years ago

Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023

Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023

Sep 27, 2023, 4:20 PM EDT - 2 years ago

Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023

Fibonacci5
Fibonacci5 Apr. 10 at 11:37 AM
$AYTU this is getting bot out.
0 · Reply
pamplon
pamplon Apr. 2 at 10:45 PM
$AYTU This is really good news https://app.quotemedia.com/data/downloadFiling?webmasterId=102691&ref=319930169&type=PDF&symbol=AYTU&cdn=f2c683ce4fe38b388f07f88e95c50879&companyName=Aytu+BioPharma%2C+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2026-04-02
3 · Reply
inv1ncible
inv1ncible Mar. 23 at 7:08 PM
$AYTU trash ceo and stock
0 · Reply
inv1ncible
inv1ncible Mar. 20 at 4:48 AM
$AYTU
0 · Reply
Lucas76
Lucas76 Mar. 19 at 9:34 PM
$AYTU Now that's impressive:
0 · Reply
termoil
termoil Mar. 18 at 3:58 PM
$AYTU If the board decides to sell then what would be a fair price per share?
1 · Reply
YourObscureCEOforLife
YourObscureCEOforLife Mar. 17 at 8:51 PM
$AYTU
0 · Reply
Alain_Simard
Alain_Simard Mar. 13 at 1:56 PM
$AYTU the only thing that $AYTU has going for it is that it doesn’t have any Iran exposure
0 · Reply
Love_To_Learn
Love_To_Learn Mar. 11 at 8:47 PM
$CDXS 1.8 key now old beloved sending code now also main 1.8 key creator $AYTU executing !
1 · Reply
mfoxx
mfoxx Mar. 11 at 5:29 PM
$AYTU when delist?
0 · Reply
Love_To_Learn
Love_To_Learn Mar. 11 at 1:09 PM
$AYTU $SIDU $BDRX MAKING CHANGES TO ALL 3 OF U
0 · Reply
MadryKielbasa
MadryKielbasa Mar. 9 at 4:54 PM
$AYTU
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 27 at 11:55 PM
$AYTU Current Stock Price: $2.57
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 26 at 7:15 PM
$AYTU RSI: 61.90, MACD: -0.0554 Vol: 0.16, MA20: 2.36, MA50: 2.52 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Pocahonta
Pocahonta Feb. 25 at 9:51 PM
$AYTU Dishbrow ain’t in jail yet? Still Trading and deceiving Investors? Where are the FEDS???
0 · Reply
Framingtheworld
Framingtheworld Feb. 23 at 7:48 AM
$AYTU $ATAI has far better product
0 · Reply
Dolphinsarecute
Dolphinsarecute Feb. 18 at 7:28 PM
$AYTU Remember that there's a tomorrow tomorrow as well! Moonshot! Give this guy a follow if you've got too much money sitting around!
3 · Reply
HiPlainsTrader
HiPlainsTrader Feb. 18 at 1:54 PM
$AYTU where’s my light!?
0 · Reply
PortfolioQuintessence
PortfolioQuintessence Feb. 17 at 1:15 PM
$AYTU Pre-revenue biotech; early-stage.
2 · Reply
TradeNiko
TradeNiko Feb. 17 at 8:50 AM
$AYTU Pre-revenue biotech; early-stage
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 13 at 2:54 AM
$AYTU Current Stock Price: $2.18
0 · Reply
CodeCatalyst
CodeCatalyst Feb. 9 at 3:14 PM
$AYTU Biotech with diversified therapeutic focus; resources are spread thin.
0 · Reply